Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Directorate Change

14 Dec 2012 07:00

RNS Number : 5188T
Immunodiagnostic Systems Hldgs PLC
14 December 2012
 



14 December 2012

 

Immunodiagnostic Systems Holdings plc

 

Chris Yates appointed as Group Finance Director

 

 

Immunodiagnostic Systems Holdings plc ("IDS"), a leading producer of manual and automated specialist diagnostic testing kits and instrumentation for the clinical and research markets, today announces that Chris Yates has been appointed Group Finance Director, with effect from 4th March 2013. 

 

Chris Yates, aged 38, joins IDS from private equity backed Nexus Vehicle Holdings Limited, where he has acted as Group Finance Director since January 2009. During his time at Nexus, as well as holding overall responsibility for finance and human resources, Chris oversaw the acquisition of Adapted Vehicle Hire Limited in May 2010.

 

From 2005 to 2007, Chris held the position of Group Finance Director at Cozart plc, allowing him to gain significant experience in the medical diagnostics industry.  During his time at Cozart, Chris led the acquisitions of four European companies: Spinreact SA (Spain), HL Scandinavia (Sweden), Nemesis Scientific Limited (UK) and Medib Skandinavien AB (Sweden) creating a pan-European medical diagnostics group. Cozart was subsequently acquired by Concateno plc (now part of Alere Inc.) in October 2007 for £64m in cash.

 

In 2008 Chris then furthered his industry expertise by acting as Co-founder and Finance Director of private specialist diagnostics company, Abingdon Health Limited.

 

From 4th March 2013 Barry Hextall, currently interim Group Finance Director, will resume his previous role as Deputy Group Finance Director.

 

Patrik Dahlen, Chief Executive Officer of IDS, commented: "It is a pleasure to announce that Chris Yates will be joining our team as Group Finance Director. As well as having a strong financial background, I am confident that Chris's knowledge and experience in the diagnostics industry will prove to be invaluable to IDS during this crucial time in the evolution of the business as a leading innovator and provider of specialist assays and diagnostic testing kits.

 

"I would also like to thank Barry Hextall for his continued support as Interim Finance Director."

 

For further information:

 

Immunodiagnostic Systems Holdings plc

Tel : +44 (0)191 519 0660

Patrik Dahlen, Chief Executive Officer

 

 

 

 

 

Peel Hunt LLP

Tel : +44 (0)207 418 8900

James Steel

 

Dr Vijay Barathan

 

 

 

FTI Consulting

Tel : +44 (0)207 831 3113

Ben Atwell

 

Simon Conway

 

Mo Noonan

 

 

 

Additional Information

Christopher Henry Francis Yates (aged 38) currently holds and has held (including all appointments during the five years preceding the date of this announcement), the following directorships and partnerships, other than the Company:

 

Current directorships:

Adapted Vehicle Hire Limited

Forsite Diagnostics Limited

Nexus VRM Limited

Nexus Vehicle Management Ltd

Nexus Vehicle Holdings Limited

Abingdon Health LTD

 

Chris currently has no shares in the Company and there are no other disclosures required pursuant to Rule 17 and Schedule 2; paragraph (g) of the AIM Rules for Companies.

 

About Immunodiagnostic Systems Holdings PLC

The Group operates in the in-vitro diagnostics ("IVD") market by designing, manufacturing and selling immunoassay kits as well as its automated analyser, the IDS-iSYS System. The IDS product range is used to measure or detect particular substances within a sample, thus aiding the diagnosis or monitoring of a disease or providing information for research studies.

 

http://www.idsplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGGGQGPUPPPWW
Date   Source Headline
7th Oct 20092:24 pmRNSAllotment of shares
5th Oct 20097:00 amRNSNon Regulatory Announcement
5th Oct 20097:00 amRNSTrading Update
24th Sep 200910:06 amRNSNew specialist assay launched for IDS-iSYS
15th Sep 20092:36 pmRNSDirector/PDMR Shareholding
4th Sep 20097:00 amRNSLicensing agreement & Directorate Change
20th Aug 20097:00 amRNSHolding(s) in Company
31st Jul 20094:02 pmRNSAGM Statement
7th Jul 20093:00 pmRNSAnnual Report and Accounts
2nd Jul 20097:00 amRNSNew specialist assay launched for IDS-iSYS
29th Jun 200912:57 pmRNSDirectors' Dealings
23rd Jun 200912:02 pmRNSIssue of Share Options
22nd Jun 20097:00 amRNSFinal Results
29th May 20097:00 amRNSChange of adviser and Notice of results
30th Apr 20092:55 pmRNSTotal Voting Rights
21st Apr 20095:03 pmRNSAdditional Listing
2nd Apr 200911:53 amRNSDirector Declaration
25th Mar 20097:00 amRNSTrading Update
2nd Mar 20097:00 amRNSIDS iSYS Launch
28th Jan 20097:00 amRNSIDS iSYS Launch Update
22nd Jan 200911:58 amRNSHolding(s) in Company
2nd Jan 20097:00 amRNSDisposal
31st Dec 200811:09 amRNSTotal Voting Rights
23rd Dec 200812:13 pmRNSHolding(s) in Company
10th Dec 20083:26 pmRNSInterim Results
10th Dec 20083:25 pmRNSIssue of Equity
14th Nov 20087:01 amRNSDisposal Update
13th Oct 20087:00 amRNSTrading Statement
2nd Oct 200811:00 amRNSAppointment of Joint Broker
29th Aug 20084:38 pmRNSResult of AGM
29th Aug 20084:35 pmRNSTotal Voting Rights
12th Aug 20085:34 pmRNSAnnual Report and AGM Notice
6th Aug 200811:56 amRNSAdditional Listing
28th Jul 20082:48 pmRNSHolding(s) in Company
14th Jul 20087:00 amRNSFinal Results
9th Jun 20087:00 amRNSDetails of Site Visit
28th May 20087:00 amRNSIndustry Award Win
2nd May 20084:16 pmRNSDirector/PDMR Shareholding
18th Apr 20087:00 amRNSIssue of Share Options
10th Apr 200810:57 amRNSDirector/PDMR Shareholding
1st Apr 20087:01 amRNSTrading update & agreement
27th Feb 200812:05 pmRNSAdditional Listing
25th Feb 20087:01 amRNSCollaboration agreement
11th Feb 20084:01 pmRNSDirector/PDMR Shareholding
11th Jan 20087:01 amRNSNew Rat/Mouse PINP Assay
27th Dec 200710:02 amRNSIssue of Options
18th Dec 200710:05 amRNSHolding(s) in Company
10th Dec 20077:01 amRNSInterim Results
3rd Dec 20079:26 amRNSChange of Adviser
21st Nov 20079:14 amRNSNotifiable Interest

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.